Methods of treating and/or preventing disorders mediated by one or more of TNF-.alpha., NF-.kappa.B, IKK-.alpha., IKK-.beta., ATF-2 and p38 kinase by administration of praziquantel, or a pharmaceutically acceptable salt, prodrug, ester or amide thereof. These disorders include inflammatory disorders such as autoimmune diseases.